close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AdvanCell

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
From AdvanCell
Via Business Wire
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
From AdvanCell
Via GlobeNewswire
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
From AdvanCell
Via GlobeNewswire
AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025
From AdvanCell
Via Business Wire
AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’
From AdvanCell
Via Business Wire
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
From AdvanCell
Via Business Wire
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
From AdvanCell
Via Business Wire
AdvanCell Expands Leadership Team with the Appointment of Christopher Horvath, MS MBA, as Chief Commercial Officer & Chief Operating Officer and Gary Li, PhD, as Chief Strategy Officer
From AdvanCell
Via Business Wire
AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer
From AdvanCell
Via Business Wire
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer
From AdvanCell
Via Business Wire
AdvanCell Closes A$18M Series B Funding Led by Morningside
From AdvanCell
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today